TFPI抗体;TFPI Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of TFPI expression in U87-MG cell lysate.    

  
  

Tissue Factor Pathway Inhibitor (TFPI) is a key anticoagulant protein that regulates the extrinsic coagulation pathway by inhibiting the tissue factor (TF)/Factor VIIa (FVIIa) complex and Factor Xa (FXa). It is primarily synthesized by vascular endothelial cells and megakaryocytes, circulating in plasma or binding to endothelial surfaces. Structurally, TFPI contains three Kunitz-type inhibitory domains: the first domain inhibits FVIIa/TF, the second targets FXa, and the third has unclear functional significance. Its anticoagulant activity involves forming a quaternary complex (TFPI-FXa-TF-FVIIa) to suppress thrombin generation.

TFPI deficiency, though rare, is linked to thrombotic disorders, while elevated levels are observed in sepsis and inflammatory conditions. Therapeutic targeting of TFPI has gained attention, particularly in hemophilia treatment. Anti-TFPI antibodies, such as concizumab, block TFPI’s inhibitory function, enhancing thrombin generation to restore hemostasis in hemophilia patients. These antibodies typically target the Kunitz 2 domain, preventing TFPI-FXa interaction. Research also explores TFPI antibodies as diagnostic tools for quantifying TFPI levels in thrombotic or bleeding disorders. However, balancing procoagulant effects with thrombosis risk remains a therapeutic challenge. Current studies focus on optimizing antibody specificity and dosing to maximize clinical efficacy while minimizing adverse events.